Anabolic Strategies to Augment Bone Fracture Healing

Scott J. Roberts 1 · Hua Zhu Ke 1

Published online: 3 May 2018 © The Author(s) 2018

Abstract

Purpose of Review The development of therapeutics that target anabolic pathways involved in skeletogenesis is of great importance with regard to disease resulting in bone loss, or in cases of impaired bone repair. This review aims to summarize recent developments in this area.

Recent Findings A greater understanding of how drugs that modulate signaling pathways involved in skeletogenesis exert their efficacy, and the molecular mechanisms resulting in bone formation has led to novel pharmacological bone repair strategies. Furthermore, crosstalk between pathways and molecules has suggested signaling synergies that may be exploited for enhanced tissue formation.

Summary The sequential pharmacological stimulation of the molecular cascades resulting in tissue repair is a promising strategy for the treatment of bone fractures. It is proposed that a therapeutic strategy which mimics the natural cascade of events observed during fracture repair may be achieved through temporal targeting of tissue repair pathways.

Keywords Bone fracture · Non-union · Anabolic pathways · Endochondral ossification

Introduction

Bone tissue has a remarkable capacity for scar-free repair following fracture. This is due to a complex interplay of signaling pathways that recapitulate many aspects of embryonic skeletal development [1, 2], which results in the coordinated regeneration of bone defects. Nevertheless, in up to approximately 10% of all cases, a bone fracture will experience delayed repair with the potential to progress to non-union, with certain bones having a higher risk of non-union, such as the tibia (up to 18.5%) [3]. A non-union is defined as the permanent failure of bone healing after 9 months with no progressive signs of repair in three consecutive months [4]. Risk factors for delayed or non-union can include characteristics of the injury, such as tissue loss or open fracture and surgical issues, including poor stabilization or infection. Host factors, however, carry a significant risk for the development of non-union and include smoking, metabolic disorders, and medication that may influence tissue repair [5]. It is therefore clear that each case of non-union may have its own unique cause, or combination of causes, and as such it is important to assess underlying mediators and stratify patients based on this. Nevertheless, a common requirement for the successful repair of a non-union fracture is the stimulation of the body’s intrinsic mechanisms for tissue repair. Currently, this is achieved through bone grafting, with autologous sources of tissue representing the gold standard, and is successful in approximately 50–80% of cases [6]. Although this technique is the standard of care, it is associated with many limitations and complications, including tissue availability, donor site pain, morbidity and infection [7]. The development of osteoanabolic drugs for the treatment of osteoporosis has created an alternative strategy for the augmentation of fracture repair, while antiresorptive agents such as bisphosphonates and denosumab appear to have some efficacy in promoting aspects of fracture repair (reviewed in [8]). Additionally, bone morphogenetic protein (BMP)-containing devices have been shown to stimulate bone formation and mediate spinal fusion [9] and non-union repair [10]; however, their use in high concentrations has been associated with an increased cancer risk [11], although this is currently disputed [12]. This review aims to summarize the most recent breakthroughs in anabolic strategies for fracture repair with a focus on preclinical data.
relating to key evidence that modulation of pathways involved in skeletogenesis can improve and indeed rescue fracture repair processes.

**Fracture Repair**

Most fractures repair through a process of endochondral ossification, in a near identical series of morphological steps to embryonic long bone development. The main exception to this is the initial production of a fracture hematoma and the presence of an inflammatory environment [1]. The hematoma is progressively replaced by a cartilaginous callus through condensation of mesenchymal cells from the periosteum in a process controlled by the concerted actions of numerous growth factors, including transforming growth factor beta 1 (TGFβ1), BMPs, fibroblast growth factors (FGFs), stromal-derived factor 1 alpha (SDF1α), and platelet-derived growth factor (PDGF) [13–17]. The importance of the periosteum in the fracture repair cascade has been extensively reviewed elsewhere [18]. The chondrocytes within the fracture callus terminally differentiate to hypertrophy, producing a mineralized matrix that acts as a scaffold for bone formation. This stage and subsequent osteoblast differentiation for bone formation is controlled, in part, through the Wnt/β-catenin pathway [19–21]. Following the progressive replacement of the mineralized cartilage matrix with bone tissue, a series of remodeling events controlled by osteoclasts and osteoblasts re-establish bone contiguity without the formation of a scar. The main exception to this process occurs if the fracture is mechanically stabilized through fixation; in this instance, there is no cartilage formation and the fracture heals through the action of osteoclasts cutting cones across the fracture line and direct (intramembranous) bone formation through the action of osteoblasts [22]. Fig. 1 details the process of long bone fracture repair and the major anabolic signaling pathways associated with each stage.

**Augmenting Fracture Repair with Parathyroid Hormone**

Parathyroid hormone (PTH) is an 84 amino acid hormone produced in response to hypocalcemia, and its primary role is to increase serum calcium levels to restore ion balance. This is achieved via the indirect (osteoblast RANK/OPG) stimulation of osteoclastogenesis which in turn sequesters calcium from the skeleton [23]. In addition to this, intermittent exposure to recombinant PTH can promote bone mass accrual [24] and this approach has since been refined to a 34 amino acid active peptide (teriparatide; PTH(1–34)), which elicits the same effects as full length PTH on the skeleton [25]. This peptide has been shown to stimulate an osteoanabolic response upon intermittent administration in both preclinical models and humans [26, 27]. Due to this activity, teriparatide was approved by the Food and Drug Administration (FDA) as the first bone anabolic agent in November 2002 for the treatment of male hypogonadal or idiopathic osteoporosis and osteoporosis in postmenopausal women at high risk of fracture. In addition to its application in osteoporosis, there is a growing body of evidence that indicates potential efficacy in the treatment of non-union bone fracture. Of interest, intermittent PTH(1–34) has been shown to promote fracture repair and improve union rate (by 59% compared to placebo) in osteopenic rats [28]. Additionally, the effect of intermittent PTH(1–34) has been investigated in the context of fracture repair in non-human primates where a dose-dependent decrease in callus porosity was observed following treatment. It was concluded that this may help to restore mechanical properties of the fracture and therefore accelerate bone healing [29].

A number of studies have been published relating to the use of teriparatide clinically for the augmentation of fracture healing. For example, 20 μg doses of teriparatide administered to female patients with a fracture of the distal radius reduced the mean time to radiographic healing to 7.4 weeks, compared with 9.1 weeks in the placebo group while doses of 40 μg had no effect, thus disproving the primary hypothesis that “teriparatide 40 μg would shorten the time to cortical bridging” [30]. Interestingly, the authors state that the apparent efficacy with 20 μg doses “should be interpreted with caution and warrants further study.” Another group reported the administration of PTH(1–84) (100 μg/day) to postmenopausal women that had suffered a pelvic fracture resulted in complete bridging of the fracture after 7.8 weeks, compared to 12.6 weeks in the control group. Encouragingly, all of the patients in the treatment group had healed after 8 weeks, compared to fewer than 10% in the control group [31]. Positive results have also been reported in studies and case reports using teriparatide in delayed and non-union fractures. Indeed, Bukata and colleagues reported 93% success in achieving union in a cohort of 145 patients with a high incidence of fracture complications (88% had failed a revision surgery, had a non-union, were elderly, or had comorbidities known to affect fracture repair), following 12 weeks of treatment with 20 μg teriparatide [32, 33]. It was noted however that repair of sites consisting of trabecular-rich regions was more rapid than those that were predominantly cortical in nature. Further positive case reports have also been published on the use of teriparatide to achieve repair in cases of delayed/non-union, or in cases where risk factors for delayed union are present (e.g., smoking) [34–39]. It should be noted that at this time, neither PTH nor any of its derivatives have been approved for the treatment of bone fracture and all the above studies represent off-label use.
Despite positive clinical evidence supporting the use of PTH for fracture repair, the precise mechanism by which it achieves its osteoanabolic response is less clear. Indeed, recent literature has indicated novel biology associated with the administration of intermittent PTH. Through conditional knockout of PTH/PTH-related peptide (PTHrP) in the limbs of developing mice, Fan and colleagues [40] reported a shift from bone formation towards high marrow adiposity and bone resorption, which the authors propose is due to increased RANKL secretion from marrow adipocytes. Interestingly, intermittent PTH administration reduces marrow adiposity, suggesting that PTH has the ability to control mesenchymal cell fate [40]. Another interesting concept when considering the effect of intermittent PTH on progenitor populations to promote bone formation/repair was uncovered through work investigating quiescent bone lining cells [41]. Lineage tracing experiments utilizing Dmp1CreERt2Rosa26R mice as a reporter allowed the monitoring of mature osteoblasts and their descendants by pulse chase. Through this technique, the authors could monitor the conversion of flat quiescent bone lining cells to cuboidal cells expressing collagen type 1 and osteocalcin, two of the major components of the organic bone matrix. This study therefore indicated that intermittent PTH treatment has the ability to increase osteoblast number by converting lining cells to mature osteoblasts in vivo [41].

In the context of cortical bone formation, which is critical for long bone repair, the effect of PTH on periosteal progenitor cells is of key importance. Indeed, periosteal progenitor cells are responsible for the formation of the fracture callus through chondrogenic differentiation, and also donate osteoblasts for later stages of the repair process. It has recently been shown that PTH has the ability to enhance the proliferation and differentiation of periosteal progenitors in murine models, potentially through Wnt/β-catenin signaling, with the net result of accelerating fracture repair [42]. This was due to enhanced bone formation, without discernible effects on the cartilage phase of fracture repair. This response was however reduced in aged mice, where incomplete resolution of the fracture callus was apparent at 42 days post-fracture [42]. Interestingly, intermittent administration of PTH(1–34) has been shown to have differing effects in trabecular and cortical bone. In trabecular bone, the
treatment elicited an increase in osteoblast number; however, there was no effect on trabecular osteocyte sclerostin expression [43]. Conversely, in cortical bone, intermittent administration of PTH(1–34) significantly reduced the number of sclerostin-positive osteocytes; however, this treatment had no effect on endosteal osteoblast number. This had the net effect of increasing trabecular bone parameters, with no effect on the cortical compartment. The finding is in line with data suggesting that the anabolic effect of PTH is not dependent on sclerostin downregulation and is linked to other mechanisms [44••]. Interestingly, this finding may provide some insight into the potential bias toward fracture repair in trabecular sites reported in the Bukata et al. clinical study [33].

Abaloparatide, which is an analog of human PTHrP(1–34), has recently gained FDA approval for the treatment of postmenopausal osteoporosis [45]. This new drug appears to have a similar mechanism of action (MOA) to teriparatide, however, it induces faster increases in bone mineral density (BMD) with larger gains at 6 months, and additional gains at sites such as the hip when compared to teriparatide [46••]. Preclinical studies in mice indicate that PTHrP has the ability to accelerate fracture repair though enhancement of callus formation and promotion of cell differentiation [47, 48]. The authors await data from the field regarding the efficacy of abaloparatide and PTHrP analogues on fracture repair in other models, and more importantly the data for clinical efficacy.

Modulation of Fracture Repair Through Wnt Signaling

The Wnt pathway is an evolutionary conserved signaling system that controls cell behavior and tissue formation, and has a key role in skeletogenesis. Although there are three Wnt signaling pathways (canonical, non-canonical planar cell polarity, and Wnt-calcium), in the context of bone targeting therapeutics, this review will concentrate on the canonical, or β-catenin dependent pathway. The canonical Wnt pathway is activated following binding of a Wnt protein to a Frizzled receptor and the LRP5/6 Wnt coreceptors, thus promoting stabilization and nuclear translocation of β-catenin to activate Wnt target gene expression. The importance of this pathway in bone homeostasis is evidenced through the identification of loss and gain of function mutations in LRP5 that resulted in low (osteoporosis pseudoglioma syndrome) [49] or high bone mass [50], respectively. Additionally, high bone mass diseases have been identified and linked to the loss of the protein sclerostin, a natural inhibitor of the Wnt signaling pathway, which binds the LRP5/6 receptors. Two similar rare diseases, which share highly similar high bone mass phenotypes, have been identified and characterized—namely sclerosteosis [51, 52] and Van Buchem disease [53, 54]. These observations led to the formulation of neutralizing antibodies against sclerostin, which deliver robust increases in BMD through a dual action in promoting osteoblast differentiation while suppressing osteoclast formation [55••, 56, 57]. Interestingly, another Wnt antagonist, Dkk1, which is temporally expressed during fracture repair and upregulated in cell populations derived from human non-union fibrous tissues [58], is also upregulated in response to treatment with sclerostin antibody [59].

Sclerostin neutralization has been previously shown to accelerate fracture repair in preclinical models, including non-human primates and rats [60, 61], with similar data associated with the inhibition of Dkk1 in rodents [62]. In an attempt to maximize the bone-forming response for fracture repair, a bi-specific antibody targeting both antagonists was formulated, and delivered significantly higher serum biomarker levels associated with bone formation in non-human primates and enhanced rat fracture repair to a greater extent than sclerostin or Dkk1 antibody alone [63••]. Indeed, administration of this bi-specific antibody dose-dependently increased callus bone volume, cross-sectional area, and torsional strength compared to sclerostin antibody (Scl-Ab) alone, which even at a high dose of 75 mg/kg resulted in non-significant increases in these parameters equivalent to 25-fold lower doses of the bi-specific antibody. It was concluded that this was not a dose-dependent effect and instead a synergy due to the combined neutralization of the two Wnt antagonists. It is hypothesized that the synergy observed is due, at least in part, to the skeleton producing Dkk1 in response to sclerostin neutralization in an attempt to self-regulate the increase in bone formation, which when neutralized with this bi-specific antibody produces an effect that is greater than inhibition of either antagonist alone. Interestingly, this synergy between Dkk1 and sclerostin has also been reported through the use of transgenic mice where bone-selective deletion of both proteins increased BMD to a greater extent than the additive effect of each alone, although the effect on fracture repair was not reported [64]. Recently, another Wnt modulator, SOSTDC1, which also functions as a BMP antagonist, has been implicated in the fracture repair process in mice, whereby loss of function promotes fracture callus formation and bone repair [65]. It is, however, unclear how this compares to sclerostin or/and Dkk1 inhibition or indeed whether antibody-targeted neutralization would be comparable to genetic deletion. In summary, although published data show that increased canonical Wnt signaling by neutralizing one or more Wnt inhibitors enhances fracture healing in union and non-union animal models, its benefits in a clinical setting is currently unknown.
Modulating the Transforming Growth Factor Beta Superfamily to Promote Fracture Repair

The transforming growth factor beta (TGFβ) superfamily of secreted factors consists of over 30 members including Activins, Nodals, bone morphogenetic proteins (BMPs), and growth and differentiation factors (GDFs). These factors have key roles from early development through to adult tissue homeostasis, with dysfunctional activity being attributed to pathology. TGFβ superfamily members signal through cell-surface serine/threonine kinase receptors and influence the phosphorylation status of Smad proteins with the result of promoting specific gene expression. In the context of bone development and repair, it is known that members of this family are involved in chondrogenesis, osteoblastogenesis, and osteoclastogenesis. As with Wnt signaling, numerous antagonists modulate this signaling pathway; however, unlike the Wnt pathway, most efforts in skeletal repair have been made in promoting signaling through addition of exogenous ligands. Indeed, much preclinical and clinical research has centered on BMP2 and BMP7, which has been reviewed extensively elsewhere and as such, will not be discussed in any detail [66]. It is however important to state that conflicting data has been reported relating to their efficacy in promoting repair of non-union fractures and safety concerns have limited their recent use. As such, efforts have centered on limiting off-target effects associated with supplying supraphysiological doses of exogenous BMP ligands to the fracture site. One such mechanism to reduce drug load would be through simultaneous or sequential stimulation of multiple pathways involved in skeletogenesis, thus better replicating the natural cascade of events observed during fracture repair. In line with this, literature suggests that simultaneously promoting BMP signaling and Wnt signaling appears to be more effective than the administration of BMP alone. Tinsley and colleagues reported impressive healing of critical sized rat femoral defects with administration of BMP alone. Tinsley and colleagues reported impressive healing of critical sized rat femoral defects with systematically administered Scl-Ab and locally implanted BMP2 when compared to BMP2-implanted animals. Indeed, following 12 weeks of treatment, all animals receiving Scl-Ab and BMP had 90% greater bone volume and improved biomechanical properties compared to the BMP group alone [67].

Advances have also been made in relation to the delivery of BMPs to the site of fracture, mainly through the use of carriers or through the use of gene transfer. Recently, it has been shown that ultrasound-mediated BMP6 transfer and expression is able to promote bone healing in a minipig critical sized defect model. In this study, endogenous mesenchymal cells were recruited into a collagen matrix followed by ultrasound-mediated gene transfer, which led to complete radiographic and functional healing in all animals after 6 weeks [68]. In a further effort to limit off-target effects of BMPs, ex vivo priming of periosteal cell populations involved in the fracture repair process with BMP2 prior to implantation in a critical size murine tibia defect has been reported. This methodology resulted in the endogenous production of physiological levels of growth and differentiation factors and robust tissue formation in a process that mimicked the fracture repair cascade [69].

In contrast to supplying soluble ligands, TGFβ receptor fusion proteins have been investigated for their effect on skeletogenesis mainly due to the role that certain ligands have in promoting bone loss. For example, it has been reported that Activin A can suppress osteoblast mineralization while promoting osteoclast formation [70, 71]. As such, ligand sinks (receptor extracellular domain-Fc) have been formulated from the major receptors of the TGFβ superfamily for the potential treatment of bone disease. Fc fusion proteins of type I BMP receptors (BMPRIA and BMPRIB) [72] and type II receptors (ActRIIA, ActRIIB) have been shown to stimulate bone mass accrual. Indeed, a soluble ActRIIA molecule was able to promote bone formation during fracture repair; however, the bone was of lesser quality compared to controls, which may be due to the negative effect of this molecule on osteoclast formation [73]. Similarly, ActRIIB-Fc has been shown to promote bone formation in mice [74]; however, its specific role in augmenting the fracture repair process has yet to be investigated. Nevertheless, it has been shown to increase bone mass in a murine model of Duchene muscular dystrophy, a disease which is characterized by muscle degeneration and a high incidence of fracture [75].

Other Pathways with Potential Applications to Non-union Fracture Repair

Platelet-Derived Growth Factor

Platelet-derived growth factor (PDGF) is a potent pro-angiogenic, mitogenic, and chemotactic factor produced by multiple cell types including vascular smooth muscle cells, macrophages, and macrophage descendants, and is known to play a number of roles within the skeletal system [76]. PDGF exists as a dimeric protein with five specific forms; AA, BB, AB, CC, and DD. The A and B forms of the protein are secreted as active ligands, whereas the C and D forms are secreted as latent forms and subsequently undergo activation by extracellular proteolytic action [77]. Recombinant human (rh) PDGF-BB is FDA approved for the treatment of chronic foot ulcers in diabetic patients, regeneration of infection-associated loss of alveolar bone, and foot and ankle fusion [78], which will be discussed in more detail later.

PDGF-BB appears to have a major function within the skeletal system, including the regulation of the initiation of fracture repair. This role is through its concerted action on angiogenesis and mesenchymal cell recruitment, proliferation, and differentiation [76], which appear in part to be due to its
effect on the JNK and ERK pathways [79]. PDGF-BB also plays a key role in bone development where its inhibition results in reduced BMD at both trabecular and cortical sites [80]. Numerous early preclinical studies have shown efficacy of PDGF to augment fracture repair, which have been reviewed elsewhere [81]. More recently, it has been reported that the transplantation of hematopoietic progenitors overexpressing PDGF-BB into mice increased trabecular bone formation and trabecular connectivity, and decreased cortical porosity, resulting in a 45% increase in bone strength [82]. This effect did, however, appear to be dose-dependent as the use of stronger gene promoters resulted in osteomalacia. It was concluded that the increase in bone parameters was due to the anabolic action of PDGF-BB on mesenchymal stem cells in the bone marrow microenvironment.

RhPDGF has been used clinically for hindfoot fusion in patients at high risk of non-union [83]. Indeed, a recent clinical trial investigating ankle and hindfoot fusion using 0.3 mg/mL rhPDGF-BB/β-TCP-collagen compared to autologous bone grafting reported that 84% of the rhPDGF-BB/β-TCP-collagen-treated patients achieved complete fusion compared to 65% of the autograft-treated patients. Furthermore, a higher percentage (91 vs. 78%) also achieved clinical success with a quicker fusion time (14.3 ± 8.9 vs. 19.7 ± 11.5 weeks) when comparing rhPDGF-BB/β-TCP-collagen patients vs. autograft patients [84]. Despite this success, no reports of the use of rhPDGF-BB to treat non-union fractures of long bones have been published to date.

**Indian Hedgehog**

The Hedgehog (Hh) proteins are evolutionary conserved across species and include Sonic Hh (Shh), Desert Hh (Dhh), and Indian Hh (Ihh), all of which signal through their receptors Patched and Smoothened. Hh proteins have a fundamental role in skeletal development in the context of embryonic limb formation and postnatal bone growth. For example, Shh is expressed in the limb bud and specifies positional values for digit formation as well as the width of the limb bud itself (reviewed in [85]). In the context of postnatal longitudinal bone growth, Ihh is expressed in the prehypertrophic zone of the growth plate and forms a negative feedback loop with PTHrP to regulate the pace of chondrocyte differentiation and therefore the rate of bone growth; interestingly, Ihh has also been reported to directly affect hypertrophy in the absence of PTHrP [86]. Ihh also appears to be involved with intramembranous ossification, with knockout mice displaying reduced cranial size [87]. In the context of this review, both Ihh and Patched are upregulated at early stages of fracture repair indicating their role in later tissue-forming events [88]. Interestingly, in a rabbit tibial defect model, the implantation of a complex of MSCs engineered to overexpress Ihh in a hydroxyapatite scaffold promoted bone repair more effectively than MSCs/scaffold alone [89]. In agreement, Ihh has recently been shown to be downregulated in dysfunctional skeletal stem cell niches in diabetic mice [90••]. The study reported that suppression of Hh signaling during fracture repair suppressed the expansion of skeletal stem cells, which retarded the normal fracture repair process. Interestingly, diabetes is a major risk factor for impaired fracture repair resulting in delayed and non-union clinically (reviewed in [91]). The investigators reported that the precise delivery of Ihh to the fracture site in a slow release hydrogel restored the repair process. It remains to be proven whether Ihh deficiency is a major cause of non-union in non-diabetic individuals and if so whether this may be a therapeutic option to treat all non-union fractures.

**Fibroblast Growth Factor 2**

Fibroblast growth factor 2 (FGF2) or basic FGF is one of a large family of growth factors that plays a role in angiogenesis and mitogenesis of multiple cell types. FGF2 signals through two (FGFR2 and FGFR3) of the four known FGF receptors (FGFRs). This signaling pathway is intrinsically linked with skeletogenesis as activating mutations in FGFR3 cause achondroplasia, hypochondroplasia, or thanatophoric dysplasia, manifesting in short stature [92]. Conversely, inactivating mutations in FGFR3 cause tall stature [93]. Although this phenotype is due to the effect of these mutations on the growth plate, FGF2 is known to be produced by osteoblasts and stored in the bone matrix. Additionally, FGF2 is expressed during the early stages of fracture repair and the receptors are expressed throughout the fracture callus [94]. Contradictory reports on the efficacy of FGF2 to promote bone repair in early preclinical models exist [95]; however, they will not be discussed in detail here. Recently, a low molecular weight (LMW) isoform of FGF2 has been investigated for its role in fracture repair. Interestingly, targeted overexpression of this isoform in the osteoblast lineage of mice caused an increase in BMD, whereas the opposite was true for all other isoforms [96]. Furthermore, BMP2 could synergize with LMW FGF2 to heal a critical sized cranial defect in LMW FGF2 transgenic mice [97]. The authors also stated that the enhanced calvarial healing was due to increased canonical Wnt signaling. In a later publication, the authors also tested the LMW FGF2 transgenic mice for tibial healing and concluded that LMW FGF2 also accelerated the fracture healing process of long bone defects [98]. Unfortunately, BMP was not co-implanted in this study so it is not evident whether similar synergies occur as seen in the calvaria. They did, however, report an increase in PDGF-BB which may contribute to the enhanced repair process. It remains to be seen whether this LMW FGF2 will deliver robust fracture repair if delivered exogenously in other animal models.
Future Perspectives

As discussed, there is a wealth of preclinical research and clinical trials ongoing to deduce the efficacy of osteo/chondro anabolic agents on the fracture repair process. The aim of this effort is to discover an agent that has the ability to overcome the failure of the biological tissue-forming cascades observed in fracture non-union. Previous preclinical studies have shown that synergies exist between signaling pathways such as BMP/Wnt, BMP/FGF2, and FGF2/PTH, that when stimulated drive more efficient fracture repair than either factor alone. It is our belief that targeting multiple anabolic signaling pathways, either simultaneously or sequentially, will induce more efficient expansion of skeletal stem cells from their niches and result in coordinated tissue formation. Through the careful selection of these pathways, a therapeutic strategy that mimics the natural cascade of events observed during fracture repair may be achieved. It is envisaged that advances in disruptive technologies that allow intracellular targeting of factors important in de novo skeletal tissue formation, along with novel antibody discovery methodologies allowing the creation bi-specific reagents, will uncover therapeutically that can initiate the body’s natural repair processes.

Compliance with Ethical Standards

Conflict of Interest Scott Roberts is a full time employee for UCB Pharma and owns stock in UCB. Hue Zhu Ke is a full time employee for UCB Pharma and owns stock in UCB and Amgen. Dr. Ke has a patent (‘Method for treating bone fracture with anti-sclerostin antibodies’ issued, owned by Amgen.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Papers of particular interest, published recently, have been highlighted as:

• Of major importance

1. Ferguson C, Alpem E, Miclau T, Helms JA. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev. 1999;87(1–2):57–66.

2. Vortkamp A, Pathi S, Peretti GM, Caruso EM, Zaleske DJ, Tabin CJ. Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech Dev. 1998;71(1–2):65–76.

3. Fong K, Truong V, Foote CJ, Petrisor B, Williams D, Ristevski B, et al. Predictors of nonunion and reoperation in patients with fractures of the tibia: an observational study. BMC Musculoskelet Disord. 2013;14:103. https://doi.org/10.1186/1471-2474-14-103.

4. Bishop JA, Palanca AA, Bellino MJ, Lowenberg DW. Assessment of compromised fracture healing. The Journal of the American Academy of Orthopaedic Surgeons. 2012;20(5):273–82. https://doi.org/10.5435/JAAOS-20-05-273.

5. Santolini E, West R, Giannoudis PV. Risk factors for long bone fracture non-union: a stratification approach based on the level of the existing scientific evidence. Injury. 2015;46(Suppl 8):S8–S19. https://doi.org/10.1016/S0020-1383(15)30049-8.

6. Zimmermann G, Wagner C, Schmeckenbecher K, Wentzensen A, Moghaddam A. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. Injury. 2009;40(Suppl 3):S50–3. https://doi.org/10.1016/S0020-1383(09)70012-9.

7. Goulet JA, Senunas LE, DeSilva GL, Greenfield ML. Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res. 1997;339:76–81.

8. Hegde V, Jo JE, Andreopoulos P, Lane JM. Effect of osteoporosis medications on fracture healing. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016;27(3):861–71. https://doi.org/10.1007/s00198-015-3331-7.

9. Papakostidis C, Kontakis G, Bhandari M, Giannoudis PV. Efficacy of autologous iliac crest bone graft and bone morpho-genetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results. Spine. 2008;33(19):E680–92. https://doi.org/10.1097/BRS.0b013e3181844eca.

10. Garrison KR, Donnell S, Ryder J, Shemilt I, Mugford M, Harvey I, et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess. 2007;11(30):1–150. iii-iv.

11. Devine JG, Dettori JR, France JC, Brodt E, McGuire RA. The use of rhBMP in spine surgery: is there a cancer risk? Evid Based Spine Care J. 2012;3(2):35–41. https://doi.org/10.1055/s-0031-1298616.

12. Cahill KS, McCormick PC, Levi AD. A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis. J Neurosurg Spine. 2015;23(1):86–93. https://doi.org/10.3171/2014.10.SPINE14338.

13. Ai-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res. 2008;87(2):107–18. https://doi.org/10.1177/154085990808700215.

14. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res. 1999;14(11):1805–15. https://doi.org/10.1056/jbmr:1999:14.11.1805.

15. Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res. 2002;17(3):513–20. https://doi.org/10.1099/jbmr.2002.17.3.513.

16. Schmid GJ, Kobayashi C, Sandell LJ, Ornitz DM. Fibroblast growth factor expression during skeletal fracture healing in mice. Dev Dyn. 2009;238(3):766–74. https://doi.org/10.1002/dvdy.21882.

 Springer
17. Yu YY, Lieu S, Lu C, Miclau T, Marcucio RS, Colnot C. Immunolocalization of BMPs, BMP antagonist receptors, and effectors during fracture repair. Bone. 2010;46(3):841–51. https://doi.org/10.1016/j.bone.2009.11.005.
18. Roberts SJ, van Gastel N, Carmeliet G, Luynen FP. Uncovering the peristium for skeletal regeneration: the stem cell that lies beneath. Bone. 2015;70:10–8. https://doi.org/10.1016/j.bone.2014.08.007.
19. Dong YF, Soung Y, Schwarz EM, O’Keefe RJ, Drissi H. Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol. 2006;208(1):77–86. https://doi.org/10.1002/jcp.20656.
20. Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med. 2007;4(7):e249. https://doi.org/10.1371/journal.pmed.0040249.
21. Wang T, Zhang X, Bikle DD. Osteogenic differentiation of periosteal cells during fracture healing. J Cell Physiol. 2017;232(5):913–21. https://doi.org/10.1002/jcp.25641.
22. Marsell R, Einhorn TA. The biology of fracture healing. Injury. 2011;42(6):551–5. https://doi.org/10.1016/j.injury.2011.03.031.
23. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Investig. 2011;34(10):801–10. https://doi.org/10.3275/7925.
24. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146(5):326–39.
25. Potts JT Jr, Tregear GW, Keuthman HT, Niall HD, Sauer R, Deftos LJ, et al. Synthesis of a biologically active N-terminal tetrahexacontapeptide of parathyroid hormone. Proc Natl Acad Sci U S A. 1971;68(1):63–7.
26. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41. https://doi.org/10.1056/NEJM200105103441904.
27. Dobni H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138(11):4607–12. https://doi.org/10.1210/endo.138.11.5505.
28. Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y. Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone. 2008;42(1):90–7. https://doi.org/10.1016/j.bone.2007.08.041.
29. Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komaebana S, et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007;40(6):1475–82. https://doi.org/10.1016/j.bone.2007.01.015.
30. Aspengren P, Genani HK, Johansson T, Nino AJ, See K, Krohn K, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14. https://doi.org/10.1359/jbmr.090731.
31. Peicht P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–7. https://doi.org/10.2106/JBJS.J.01379.
32. Bukata SV, Kaback LA, Reynolds DG, O’Keefe RJ, Rosier RN. 1–34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society Las Vegas, NV; February 25, 2009.
33. Bukata SV, Puzas JE. Orthopedic uses of teriparatide. Current osteoporosis reports. 2010;8(1):28–33. https://doi.org/10.1007/s11914-010-0006-3.
34. Chintamaneni S, Finzel K, Gruber BL. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2010;21(6):1059–63. https://doi.org/10.1007/s00198-009-1061-4.
35. Kastir I, Radmer S, Andresen R, Schober HC. Osseous consolidation of an aseptic delayed union of a lower leg fracture after parathyroid hormone therapy—a case report. J Clin Diagn Res. 2016;10(7):RD03–5. https://doi.org/10.7860/JCDR/2016/20006.8203.
36. Matsumoto T, Ando M, Sasaki S. Effective treatment of delayed union of a lumbar vertebral fracture with daily administration of teriparatide in a patient with diffuse idiopathic skeletal hyperostosis. Eur Spine J. 2015;24(4 Suppl 4):S573–6. https://doi.org/10.1007/s00586-014-3733-9.
37. Ochi K, Ikari K, Naomi A, Momohara S. Administration of teriparatide for treatment as a challenging case of nonunion of periprosthetic fracture after total knee arthroplasty. Arch Osteoporos. 2013;8:159. https://doi.org/10.1007/s11657-013-0159-7.
38. Rubery PT, Bukata SV. Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: a report of 3 cases. J Spinal Disord Tech. 2010;23(2):151–5. https://doi.org/10.1097/BSD.0b013e31819a8b7a.
39. Xiaofeng L, Daxia X, Yunzhen C. Teriparatide as a nonoperative treatment for tibial and femoral fracture nonunion: a case report. Medicine. 2017;96(16):e6571. https://doi.org/10.1097/MD.0000000000006571.
40. Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab. 2017;25(3):661–72. https://doi.org/10.1016/j.cmet.2017.01.001.
41. Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. Journal of bone and mineral research. 2012;27(10):671–82. https://doi.org/10.1002/jbmr.1665.
42. Yukata K, Xie C, Li TF, Takahata M, Hoak D, Konabolu S, et al. Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1-34 treatment. Bone. 2014;62:79–89. https://doi.org/10.1016/j.bone.2014.02.002.
43. Ogura K, Iimura T, Makino Y, Sugie-Oya A, Takakura A, Takao-Kawabata R, et al. Short-term intermittent administration of parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical bone. Bone reports. 2016;5:7–14. https://doi.org/10.1016/j.bonr.2016.01.002.
44. Delgado-Calle J, Tu X, Pacheco-Costa R, McAndrews K, Edwards R, Pellegrini GG, et al. Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017;32(3):522–35. https://doi.org/10.1002/jbmr.3011. This study further elucidates the mechanism by which PTH exerts its efficacy.
45. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&kvarApplNo=208743. 2017.

© Springer
46. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136. This is manuscript reports on a clinical trial to determine the efficacy of Abaloparatide (PThPr analog) in postmenopausal osteoporosis.

47. Wang Y, Fang X, Wang C, Ding C, Lin H, Liu A, et al. Exogenous PThPr repairs the damaged fracture healing of PThPr+/− mice and accelerates fracture healing of wild mice. Int J Mol Sci. 2017;18(2) https://doi.org/10.3390/ijms18020337.

48. Liu A, Li Y, Wang Y, Liu L, Shi H, Qiu Y. Exogenous parathyroid hormone-related peptide promotes fracture healing in Leptr(−/−) mice. Calcif Tissue Int. 2015;97(6):581–91. https://doi.org/10.1007/s00223-015-0414-2.

49. Gong Y, Sleeb RB, Fukai N, Rawadi G, Roman-Roman S, Regnato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–23.

50. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21. https://doi.org/10.1056/NEJMoa013444.

51. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537–43.

52. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–89.

53. Balemans W, Patel N, Ebeling M, Van Hul E, Wyants W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91–7.

54. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110(2):144–52. https://doi.org/10.1002/ajmg.10401.

55. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czervinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948. This is manuscript reports on a clinical trial to determine the efficacy of Romosozumab (anti-Sclerostin antibody) in postmenopausal osteoporosis.

56. McClung MR, Grauer A, Boonen S, Bolognesi MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. https://doi.org/10.1056/NEJMoa1305224.

57. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(5):1012–21. https://doi.org/10.1002/jbmr.307.

58. Ke HZ, Richards WG, Li X, Ominsky MS. sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33(5):747–83. https://doi.org/10.1210/er.2011-1060.

59. Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res. 2011;26(11):2610–21. https://doi.org/10.1002/jbmr.472.

60. Ominsky MS, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26(5):1012–21. https://doi.org/10.1002/jbmr.307.
Tickle ES, DiGiovanni CW. The efficacy of platelet-derived growth factor as a bone-stimulating agent. Foot Ankle Clin. 2016;21(4):763–70. https://doi.org/10.1016/j.fcl.2016.07.002.

79. Mehrotra M, Krane SM, Walters K, Pilebeam C. Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem. 2004;93(4):741–52. https://doi.org/10.1002/jcb.20138.

80. Xie H, Cui Z, Wang L, Xia Z, Hu Y, Xian L, et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med. 2014;20(11):1270–7. https://doi.org/10.1038/nm.3668.

81. Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am. 2008;90(Suppl 1):48–54. https://doi.org/10.2106/JBJS.G.01231.

82. Chen W, Baylink DJ, Brier-Jones I, Neises A, Kiroyan JB, Rundle CH, et al. PDGFB-based stem cell gene therapy increases bone strength in the mouse. Proc Natl Acad Sci U S A. 2015;112(29):E3893–900. https://doi.org/10.1073/pnas.1501759112.

83. Dodd A, Daniels TR. Injectable recombinant human platelet-derived growth factor in collagen carrier for hindfoot fusion. Foot Ankle Clin. 2016;21(4):777–91. https://doi.org/10.1016/j.fcl.2016.07.013.

84. Daniels TR, Younger AS, Penner MJ, Wing KJ, Le IL, Russell IS, et al. Prospective randomized controlled trial of hindfoot and ankle fusions treated with rhPDGF-BB in combination with a beta-TCP-collagen matrix. Foot Ankle Int. 2015;36(7):739–48. https://doi.org/10.1177/1070326615576370.

85. Tickle C, Towers M. Sonic hedgehog signaling in limb development. Front Cell Dev Biol. 2017;5:14. https://doi.org/10.3389/fcell.2017.00014.

86. Mak KK, Kronenberg HM, Chuang PT, Mackern S, Yang Y. Indian hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy. Development. 2008;135(11):1947–56. https://doi.org/10.1242/dev.018044.

87. Lenton K, James AW, Manu A, Brugmann SA, Birker D, Nelson ER, et al. Indian hedgehog positively regulates calvarial ossification and modulates bone morphogenic protein signaling. Genesis. 2011;49(10):784–96. https://doi.org/10.1002/dvg.20768.

88. Ito H, Akiyama H, Shigeno C, Iyama K, Matsuoka H, Nakamura T. Hedgehog signaling molecules in bone marrow cells at the initial stage of fracture repair. Biochem Biophys Res Commun. 1999;262(2):443–51. https://doi.org/10.1006/bbrc.1999.1197.

89. Zou S, Chen T, Wang Y, Tian R, Zhang L, Song P, et al. Mesenchymal stem cells overexpressing Ihh promote bone repair. J Orthop Surg Res. 2014;9:102. https://doi.org/10.1186/s13018-014-0102-7.

90. Tevlin R, Seo YE, Marcic O, Mc Ardle A, Tong X, Zimdahl B, Malkovskiy A, Sinha R, Gulati G, Li X, Wearda T, Morganti R, Lopez M, Ransom RC, Duldulao CR, Rodrigues M, Nguyen A, Januszky M, Maan Z, Paik K, Yapa KS, Rajadas J, Wan DC, Gurtner GC, Snyder M, Beachy PA, Yang F, Goodman SB, Weissman IL, Chan CKF, Longaker MT Pharmacological rescue of diabetic skeletal stem cell niches. Sci Transl Med. 2017;9(372). https://doi.org/10.1126/scitranslmed.aag2809. This study details how Ihh can rescue impaired fracture repair in diabetic mice.

91. Jiao H, Xiao E, Graves DT. Diabetes and its effect on bone and fracture healing. Curr Osteoporos Rep. 2015;13(5):327–35. https://doi.org/10.1007/s11914-015-0286-8.

92. Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Developmental dynamics: an official publication of the American Association of Anatomists. 2017;246(4):291–309. https://doi.org/10.1002/dvdy.24479.

93. Makrythanasis P, Tehtamy S, Aglan MS, Otary GA, Hamamy H, Antonarakis SE. A novel homozygous mutation in FGF3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly. Hum Mutat. 2014;35(8):959–63. https://doi.org/10.1002/humu.22597.

94. Rundle CH, Miyakoshi N, Ramirez E, Wergedal JE, Lau KH, Baylink DJ. Expression of the fibroblast growth factor receptor genes in fracture repair. Clin Orthop Relat Res. 2002;403:253–63.

95. Xiao L, Ueno D, Catros S, Homer-Bouthiette C, Charles L, Kuhn L, et al. Fibroblast growth factor-2 isoform (low molecular weight/18 kDa) overexpression in preosteoblast cells promotes bone regeneration in critical size calvarial defects in male mice. Endocrinology. 2014;155(3):965–74. https://doi.org/10.1210/en.2013-1919.

96. Hurley MM, Adams DJ, Wang L, Jiang X, Burt PM, Du E, et al. Accelerated fracture healing in transgenic mice overexpressing an anabolic isoform of fibroblast growth factor 2. J Cell Biochem. 2016;117(3):599–611. https://doi.org/10.1002/jcb.25308.

97. Shah P, Keppler L, Rutkowski J. A review of platelet derived growth factors in regulation of fracture healing biology and potential clinical applications. Mediat Inflamm. 2015;2015:137823.

98. Poniatowski LA, Wójciszewi cz P, Gasik R, Szukiewicz D. Treatment with soluble activin type IIB-receptor modulates bone healing in the diabetic mouse model. Diabetes Metab Syndr Obes. 2010;3:79–82. https://doi.org/10.2147/dms.s100044.

99. Shah P, Keppler L, Rutkowski J. A review of platelet derived growth factors in regulation of fracture healing biology and potential clinical applications. Mediat Inflamm. 2015;2015:137823.